Using Allopurinol and Trimetazidine to Prevent Kidney Injury in PCI Patients
Allopurinol and Trimetazidine as a Preventive of Contrast-associated Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention
This study tests if using allopurinol and trimetazidine can help prevent kidney damage in patients at risk while they undergo a heart procedure called PCI.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 124 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Beni-Suef University Academic / other |
| Locations | 1 site (Banī Suwayf, Beni-Suef) |
| Trial ID | NCT05540184 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of allopurinol and trimetazidine in preventing contrast-associated acute kidney injury (CA-AKI) in patients undergoing percutaneous coronary intervention (PCI). The study aims to enroll patients at varying risk levels for CA-AKI, based on the Mehran risk score, and will administer the medications alongside normal saline hydration. By monitoring serum creatinine levels, the trial seeks to determine if these interventions can reduce the incidence of CA-AKI and its associated complications. The findings could lead to improved protocols for protecting kidney function during PCI procedures.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 80 who are scheduled for PCI and assessed to be at low, moderate, or high risk for contrast-induced nephropathy.
Not a fit: Patients with existing acute kidney injury, renal insufficiency, or those with contraindications to the study medications will not benefit from this trial.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of acute kidney injury in patients undergoing PCI, leading to better outcomes and lower healthcare costs.
How similar studies have performed: Previous studies have explored various interventions for preventing CA-AKI, but the specific combination of allopurinol and trimetazidine in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients willing to undergo PCI with low, moderate or high risk of CIN based on Mehran risk score (4) * Age 18 - 80 years * Patients with GFR \> 60 ml/min Exclusion Criteria: * Age \<18 or \> 80 years * Acute kidney injury * Renal insufficiency (eGFR \< 60 mL/min) * Gout (serum uric \> 10 mg/dL) * History of allopurinol intake. * Hepatic failure. * Pregnancy or lactation, * History of allergy to contrast agents, allopurinol or trimetazidine * Any nephrotoxic drug intake within 48 hrs. before the procedure * Pulmonary edema, cardiogenic shock and mechanical ventilation.
Where this trial is running
Banī Suwayf, Beni-Suef
- Faculty of Pharmacy, Beni-Suef University — Banī Suwayf, Beni-Suef, Egypt (Recruiting)
Study contacts
- Principal investigator: Naglaa Samir Bazan, Assoc. Prof — clinical pharmacy critical care medicine, Cairo university
- Study coordinator: Nourhan Osama Ali Moselhy, BSc
- Email: norhanossama15@yahoo.com
- Phone: 01117115773
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.